Table Info

Table 2.

Vitamin D supplementation and incidence of infections

Condition	Age/years old	Study	Results	Reference
Healthy community	Mean 59	Supplementation 50 mg/day in winter	No decrease in the severity and duration of upper respiratory infection	[74]
Residents (skilled nursing/assisted living facilities)	80 ± 10	High dose of 4,000 IU/day or standard dose of 400–1,000 IU/day followed for 12 months	Upper acute respiratory infection (ARI), skin and soft tissue infections are lower in the high dose group. All-cause hospitalization and death similar in both groups	[75]
Bone fracture	Mean 77	Supplementation of 800 IU vitamin D daily	Fewer infection events, and decreased use of antibiotics than the placebo group but the results were not statistically different	[77]
Patients: antibody deficiency/increased susceptibility to infections	18–75	12 months supplementation (4,000 IU/day oral)	Decrease in respiratory tract infections and prolonged time to the first respiratory tract infections (RTI) x placebo	[79]
Sepsis/septic shock patients	55–70	Supplementation 200,000 IU or 400,000 IU vitamin D single bolus	Higher levels of LL-37 and IFN-γ, reduced hospital length stay, and 30-day readmission	[80]

Declarations

Author contributions

VB: Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The study was supported by CAPES PrInt UNIFESP [88881.310735/2018-01]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Centers for Disease Control and Prevention [Internet]. Georgia: The Association; c2020-2023 [cited 2023 Mar 14]. Deaths by Select Demographic and Geographic Characteristics; [about 1 screen]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/#SexAndAge

Salimi S, Hamlyn JM. COVID-19 and crosstalk with the hallmarks of aging. J Gerontol A Biol Sci Med Sci. 2020;75:e34–41. [DOI] [PubMed] [PMC]

Cristina ML, Spagnolo AM, Giribone L, Demartini A, Sartini M. Epidemiology and prevention of healthcare-associated infections in geriatric patients: a narrative review. Int J Environ Res Public Health. 2021;18:5333. [DOI] [PubMed] [PMC]

Fantini C, Corinaldesi C, Lenzi A, Migliaccio S, Crescioli C. Vitamin D as a shield against aging. Int J Mol Sci. 2023;24:4546. [DOI] [PubMed] [PMC]

Effros RB. Genetic alterations in the ageing immune system: impact on infection and cancer. Mech Ageing Dev. 2003;124:71–7. [DOI] [PubMed]

Weinberger B. Vaccination of older adults: influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing. 2021;18:38. [DOI] [PubMed] [PMC]

Duggal NA, Niemiro G, Harridge SDR, Simpson RJ, Lord JM. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol. 2019;19:563–72. [DOI] [PubMed]

Sellami M, Gasmi M, Denham J, Hayes LD, Stratton D, Padulo J, et al. Effects of acute and chronic exercise on immunological parameters in the elderly aged: can physical activity counteract the effects of aging? Front Immunol. 2018;9:2187. [DOI] [PubMed] [PMC]

Tylutka A, Morawin B, Gramacki A, Zembron-Lacny A. Lifestyle exercise attenuates immunosenescence; flow cytometry analysis. BMC Geriatr. 2021;21:200. [DOI] [PubMed] [PMC]

10.

Sharma R, Diwan B, Sharma A, Witkowski JM. Emerging cellular senescence-centric understanding of immunological aging and its potential modulation through dietary bioactive components. Biogerontology. 2022;23:699–729. [DOI] [PubMed] [PMC]

11.

Sharma R, Padwad Y. Nutraceuticals-based immunotherapeutic concepts and opportunities for the mitigation of cellular senescence and aging: a narrative review. Ageing Res Rev. 2020;63:101141. [DOI] [PubMed]

12.

Rekha RS, Mily A, Sultana T, Haq A, Ahmed S, Mostafa Kamal SM, et al. Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D₃ as host directed therapy. BMC Infect Dis. 2018;18:303. [DOI] [PubMed] [PMC]

13.

Bartley J, Garrett J, Camargo CA Jr, Scragg R, Vandal A, Sisk R, et al. Vitamin D₃ supplementation in adults with bronchiectasis: a pilot study. Chron Respir Dis. 2018;15:384–92. [DOI] [PubMed] [PMC]

14.

Mily A, Rekha RS, Kamal SM, Akhtar E, Sarker P, Rahim Z, et al. Oral intake of phenylbutyrate with or without vitamin D₃ upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis. BMC Pulm Med. 2013;13:23. [DOI] [PubMed] [PMC]

15.

Klug-Micu GM, Stenger S, Sommer A, Liu PT, Krutzik SR, Modlin RL, et al. CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes. Immunology. 2013;139:121–8. [DOI] [PubMed] [PMC]

16.

Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D₃ in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983;57:1308–10. [DOI] [PubMed]

17.

Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D₃ receptor in the immune system. Arch Biochem Biophys. 2000;374:334–8. [DOI] [PubMed]

18.

Erdoğan M, Fındıklı HA. Novel biomarker for predicting sepsis mortality: vitamin D receptor. J Int Med Res. 2021;49:3000605211034733. [DOI] [PubMed] [PMC]

19.

Goncalves-Mendes N, Talvas J, Dualé C, Guttmann A, Corbin V, Marceau G, et al. Impact of Vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial. Front Immunol. 2019;10:65. [DOI] [PubMed] [PMC]

20.

Dramé M, Cofais C, Hentzien M, Proye E, Coulibaly PS, Demoustier-Tampère D, et al. Relation between Vitamin D and COVID-19 in aged people: a systematic review. Nutrients. 2021;13:1339. [DOI] [PubMed] [PMC]

21.

Pham H, Waterhouse M, Baxter C, Duarte Romero B, McLeod DSA, Armstrong BK, et al. Vitamin D supplementation and antibiotic use in older Australian adults: an analysis of data from the D-health trial. J Infect Dis. 2022;226:949–57. [DOI] [PubMed]

22.

Borras C, Ingles M, Mas-Bargues C, Dromant M, Sanz-Ros J, Román-Domínguez A, et al. Centenarians: an excellent example of resilience for successful ageing. Mech Ageing Dev. 2020;186:111199. [DOI] [PubMed]

23.

Alonso-Fernández P, De la Fuente M. Role of the immune system in aging and longevity. Curr Aging Sci. 2011;4:78–100. [DOI] [PubMed]

24.

Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26–34. [DOI] [PubMed] [PMC]

25.

MacDonell SO, Miller JC, Harper MJ, Waters DL, Houghton LA. Vitamin D status and its predictors in New Zealand aged-care residents eligible for a government-funded universal vitamin D supplementation programme. Public Health Nutr. 2016;19:3349–60. [DOI] [PubMed] [PMC]

26.

Moyersoen I, Devleesschauwer B, Dekkers A, de Ridder K, Tafforeau J, van Camp J, et al. Intake of fat-soluble vitamins in the Belgian population: adequacy and contribution of foods, fortified foods and supplements. Nutrients. 2017;9:860. [DOI] [PubMed] [PMC]

27.

Walker P, Miller Amberber A, Kurrle S, Kifley A, Cameron ID. Prevalence of vitamin D supplement use in Australian residential aged care facilities in November 2014. BMC Res Notes. 2017;10:385. [DOI] [PubMed] [PMC]

28.

Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011;7:337–45. [DOI] [PubMed]

29.

Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88:720–55. [DOI] [PubMed] [PMC]

30.

Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59:881–6. [DOI] [PubMed] [PMC]

31.

Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662–87. [DOI] [PubMed]

32.

Gottfried E, Rehli M, Hahn J, Holler E, Andreesen R, Kreutz M. Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun. 2006;349:209–13. [DOI] [PubMed]

33.

Wu S, Ren S, Nguyen L, Adams JS, Hewison M. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D₃ production. Endocrinology. 2007;148:3410–8. [DOI] [PubMed]

34.

van Etten E, Stoffels K, Gysemans C, Mathieu C, Overbergh L. Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev. 2008;66:S125–34. [DOI] [PubMed]

35.

Capri M, Monti D, Salvioli S, Lescai F, Pierini M, Altilia S, et al. Complexity of anti-immunosenescence strategies in humans. Artif Organs. 2006;30:730–42. [DOI] [PubMed]

36.

Olliver M, Spelmink L, Hiew J, Meyer-Hoffert U, Henriques-Normark B, Bergman P. Immunomodulatory effects of vitamin D on innate and adaptive immune responses to Streptococcus pneumoniae. J Infect Dis. 2013;208:1474–81. [DOI] [PubMed]

37.

Rode AKO, Kongsbak M, Hansen MM, Lopez DV, Levring TB, Woetmann A, et al. Vitamin D counteracts Mycobacterium tuberculosis-induced cathelicidin downregulation in dendritic cells and allows Th1 differentiation and IFNγ secretion. Front Immunol. 2017;8:656. [DOI] [PubMed] [PMC]

38.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3. [DOI] [PubMed]

39.

Wong JH, Ye XJ, Ng TB. Cathelicidins: peptides with antimicrobial, immunomodulatory, anti-inflammatory, angiogenic, anticancer and procancer activities. Curr Protein Pept Sci. 2013;14:504–14. [DOI] [PubMed]

40.

Lowry MB, Guo C, Borregaard N, Gombart AF. Regulation of the human cathelicidin antimicrobial peptide gene by 1α,25-dihydroxyvitamin D₃ in primary immune cells. J Steroid Biochem Mol Biol. 2014;143:183–91. [DOI] [PubMed] [PMC]

41.

Alvarez-Rodriguez L, Lopez-Hoyos M, Garcia-Unzueta M, Amado JA, Cacho PM, Martinez-Taboada VM. Age and low levels of circulating vitamin D are associated with impaired innate immune function. J Leukoc Biol. 2012;91:829–38. [DOI] [PubMed]

42.

Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, et al. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res. 2017;137:93–101. [DOI] [PubMed]

43.

De Vita F, Lauretani F, Bauer J, Bautmans I, Shardell M, Cherubini A, et al. Relationship between vitamin D and inflammatory markers in older individuals. Age (Dordr). 2014;36:9694. [DOI] [PubMed] [PMC]

44.

de Oliveira C, Biddulph JP, Hirani V, Schneider IJC. Vitamin D and inflammatory markers: cross-sectional analyses using data from the English Longitudinal Study of Ageing (ELSA). J Nutr Sci. 2017;6:e1. [DOI] [PubMed] [PMC]

45.

Ma YH, Zhou YL, Yue CY, Zhang GH, Deng L, Xie GH, et al. Vitamin D deficiency contributes to the reduction and impaired function of naïve CD45RA⁺ regulatory T cell in chronic heart failure. J Immunol Res. 2015;2015:547697. [DOI] [PubMed] [PMC]

46.

Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood. 2005;105:2294–9. [DOI] [PubMed] [PMC]

47.

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54. [DOI] [PubMed]

48.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34. [DOI] [PubMed]

49.

Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:2413–8. [DOI] [PubMed]

50.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81. [DOI] [PubMed]

51.

Pletz MW, Terkamp C, Schumacher U, Rohde G, Schütte H, Welte T, et al.; CAPNETZ-Study Group. Vitamin D deficiency in community-acquired pneumonia: low levels of 1,25(OH)2 D are associated with disease severity. Respir Res. 2014;15:53. [DOI] [PubMed] [PMC]

52.

Umehara K, Mukai N, Hata J, Hirakawa Y, Ohara T, Yoshida D, et al. Association between serum Vitamin D and all-cause and cause-specific death in a general Japanese population—the Hisayama study. Circ J. 2017;81:1315–21. [DOI] [PubMed]

53.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28. [DOI] [PubMed]

54.

Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al.; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–20. [DOI] [PubMed]

55.

Godar DE, Pope SJ, Grant WB, Holick MF. Solar UV doses of young Americans and vitamin D₃ production. Environ Health Perspect. 2012;120:139–43. [DOI] [PubMed] [PMC]

56.

MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D₃. J Clin Invest. 1985;76:1536–8. [DOI] [PubMed] [PMC]

57.

Theiler R, Stähelin HB, Tyndall A, Binder K, Somorjai G, Bischoff HA. Calcidiol, calcitriol and parathyroid hormone serum concentrations in institutionalized and ambulatory elderly in Switzerland. Int J Vitam Nutr Res. 1999;69:96–105. [DOI] [PubMed]

58.

Hilger J, Friedel A, Herr R, Rausch T, Roos F, Wahl DA, et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr. 2014;111:23–45. [DOI] [PubMed]

59.

Semba RD, Houston DK, Ferrucci L, Cappola AR, Sun K, Guralnik JM, et al. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women. Nutr Res. 2009;29:525–30. [DOI] [PubMed] [PMC]

60.

Formiga F, Ferrer A, Megido MJ, Boix L, Contra A, Pujol R; Octabaix study members. Low serum vitamin D is not associated with an increase in mortality in oldest old subjects: the Octabaix three-year follow-up study. Gerontology. 2014;60:10–5. [DOI] [PubMed]

61.

ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr. 2002;26:1SA–138SA. Erratum in: JPEN J Parenter Enteral Nutr. 2002;26:144. [PubMed]

62.

Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204–10. [DOI] [PubMed]

63.

Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab. 2003;88:4623–32. [DOI] [PubMed]

64.

Berry DJ, Hesketh K, Power C, Hyppönen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br J Nutr. 2011;106:1433–40. [DOI] [PubMed]

65.

Balcells ME, García P, Tiznado C, Villarroel L, Scioscia N, Carvajal C, et al. Association of vitamin D deficiency, season of the year, and latent tuberculosis infection among household contacts. PLoS One. 2017;12:e0175400. [DOI] [PubMed] [PMC]

66.

Khoo AL, Koenen HJ, Chai LY, Sweep FC, Netea MG, van der Ven AJ, Joosten I. Seasonal variation in vitamin D₃ levels is paralleled by changes in the peripheral blood human T cell compartment. PLoS One. 2012;7:e29250. [DOI] [PubMed] [PMC]

67.

Aregbesola A, Voutilainen S, Nurmi T, Virtanen JK, Ronkainen K, Tuomainen TP. Serum 25-hydroxyvitamin D₃ and the risk of pneumonia in an ageing general population. J Epidemiol Community Health. 2013;67:533–6. [DOI] [PubMed]

68.

Parekh D, Patel JM, Scott A, Lax S, Dancer RC, D’Souza V, et al. Vitamin D deficiency in human and murine sepsis. Crit Care Med. 2017;45:282–9. [DOI] [PubMed] [PMC]

69.

Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology. 2011;16:611–6. [DOI] [PubMed]

70.

De Pascale G, Vallecoccia MS, Schiattarella A, Di Gravio V, Cutuli SL, Bello G, et al. Clinical and microbiological outcome in septic patients with extremely low 25-hydroxyvitamin D levels at initiation of critical care. Clin Microbiol Infect. 2016;22:456.e7–13. [DOI] [PubMed]

71.

Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28. [DOI] [PubMed] [PMC]

72.

Sundaram ME, Talbot HK, Zhu Y, Griffin MR, Spencer S, Shay DK, et al. Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. Vaccine. 2013;31:2057–61. [DOI] [PubMed]

73.

Sadarangani SP, Ovsyannikova IG, Goergen K, Grill DE, Poland GA. Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons. Hum Vaccin Immunother. 2016;12:691–8. [DOI] [PubMed] [PMC]

74.

Li-Ng M, Aloia JF, Pollack S, Cunha BA, Mikhail M, Yeh J, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;137:1396–404. [DOI] [PubMed]

75.

Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, et al. High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial. J Am Geriatr Soc. 2017;65:496–503. [DOI] [PubMed] [PMC]

76.

Martineau AR, Hanifa Y, Witt KD, Barnes NC, Hooper RL, Patel M, et al. Double-blind randomised controlled trial of vitamin D₃ supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax. 2015;70:953–60. [DOI] [PubMed]

77.

Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2007;36:574–7. [DOI] [PubMed]

78.

Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D₃ supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308:1333–9. [DOI] [PubMed]

79.

Bergman P, Norlin AC, Hansen S, Björkhem-Bergman L. Vitamin D supplementation improves well-being in patients with frequent respiratory tract infections: a post hoc analysis of a randomized, placebo-controlled trial. BMC Res Notes. 2015;8:498. [DOI] [PubMed] [PMC]

80.

Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, et al. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: a randomized, placebo-controlled trial. Crit Care Med. 2015;43:1928–37. [DOI] [PubMed] [PMC]

81.

Peelen E, Rijkers G, Meerveld-Eggink A, Meijvis S, Vogt M, Cohen Tervaert JW, et al. Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria. Eur J Clin Microbiol Infect Dis. 2013;32:61–9. [DOI] [PubMed]

82.

Kriesel JD, Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine. 1999;17:1883–8. [DOI] [PubMed]

83.

Heine G, Drozdenko G, Lahl A, Unterwalder N, Mei H, Volk HD, et al. Efficient tetanus toxoid immunization on vitamin D supplementation. Eur J Clin Nutr. 2011;65:329–34. [DOI] [PubMed]

84.

Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al.; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345–55. [DOI] [PubMed] [PMC]

85.

Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan detroit. JAMA Netw Open. 2020;3:e2012270. [DOI] [PubMed] [PMC]

86.

Ferrando C, Mellado-Artigas R, Gea A, Arruti E, Aldecoa C, Bordell A, et al.; de la Red de UCI Española para COVID-19. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: a prospective, cohort, multicentre study. Rev Esp Anestesiol Reanim (Engl Ed). 2020;67:425–37. English, Spanish. [DOI] [PubMed] [PMC]

87.

Infante M, Buoso A, Pieri M, Lupisella S, Nuccetelli M, Bernardini S, et al. Low vitamin D status at admission as a risk factor for poor survival in hospitalized patients with COVID-19: an Italian retrospective study. J Am Nutr Assoc. 2022;41:250–65. [DOI] [PubMed] [PMC]

88.

Oscanoa TJ, Amado J, Vidal X, Laird E, Ghashut RA, Romero-Ortuno R. The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration—a metaanalysis. Adv Respir Med. 2021;89:145–57. [DOI] [PubMed]

89.

Soltani-Zangbar MS, Mahmoodpoor A, Dolati S, Shamekh A, Valizadeh S, Yousefi M, et al. Serum levels of vitamin D and immune system function in patients with COVID-19 admitted to intensive care unit. Gene Rep. 2022;26:101509. [DOI] [PubMed] [PMC]

90.

Bayraktar N, Turan H, Bayraktar M, Ozturk A, Erdoğdu H. Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID-19. J Med Virol. 2022;94:154–60. [DOI] [PubMed] [PMC]

91.

Szeto B, Zucker JE, LaSota ED, Rubin MR, Walker MD, Yin MT, et al. Vitamin D status and COVID-19 clinical outcomes in hospitalized patients. Endocr Res. 2021;46:66–73. [DOI] [PubMed] [PMC]

92.

Sarhan N, Abou Warda AE, Sarhan RM, Boshra MS, Mostafa-Hedeab G, ALruwaili BF, et al. Evidence for the efficacy of a high dose of vitamin D on the hyperinflammation state in moderate-to-severe COVID-19 patients: a randomized clinical trial. Medicina (Kaunas). 2022;58:1358. [DOI] [PubMed] [PMC]

93.

Mariani J, Antonietti L, Tajer C, Ferder L, Inserra F, Sanchez Cunto M, et al. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: multicentre randomized controlled clinical trial. PLoS One. 2022;17:e0267918. [DOI] [PubMed] [PMC]

94.

Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D₃ on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325:1053–60. [DOI] [PubMed] [PMC]

95.

Jolliffe DA, Vivaldi G, Chambers ES, Cai W, Li W, Faustini SE, et al. Vitamin D supplementation does not influence SARS-CoV-2 vaccine efficacy or immunogenicity: sub-studies nested within the CORONAVIT randomised controlled trial. Nutrients. 2022;14:3821. [DOI] [PubMed] [PMC]

96.

Piec I, Cook L, Dervisevic S, Fraser WD, Ruetten S, Berman M, et al. Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine. Curr Res Transl Med. 2022;70:103344. [DOI] [PubMed] [PMC]

97.

Zelini P, d’Angelo P, Cereda E, Klersy C, Sabrina P, Albertini R, et al. Association between Vitamin D serum levels and immune response to the BNT162b2 vaccine for SARS-CoV-2. Biomedicines. 2022;10:1993. [DOI] [PubMed] [PMC]

98.

Rachman A, Iriani A, Priantono D, Rumondor BB, Betsy R, Juanputra S. The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines. Front Nutr. 2022;9:1066411. [DOI] [PubMed] [PMC]

99.

Velikova T, Fabbri A, Infante M. The role of vitamin D as a potential adjuvant for COVID-19 vaccines. Eur Rev Med Pharmacol Sci. 2021;25:5323–7. [DOI] [PubMed]